Testicular Cancer, An Issue of Urologic Clinics

Daniel W. Lin

Description

This issue provides much needed updates since Dr. Sheinfeld’s issue published in 2007. Dr. Lin has assembled expert authors to provide clinicians with the full breadth of clinical updates on testicular cancer. New to this issue are articles on clinical outcomes, survivorship, and several articles on the management of Nonseminomatous Germ Cell Tumors.

Sujets

• Médecine
• Médecine Générale
• Medical
• Urology

Informations

• Publié par: Elsevier
• Date de parution: 29 juillet 2015
• Nombre de lectures: 0
• EAN13: 9780323393614
• Langue: English
• Poids de l'ouvrage: 3 Mo

Extrait

Clinics Review Articles Urologic Clinics of North America
Testicular Cancer

Daniel W. Lin, MD
Department of Urology, University of Washington, Seattle, WA, USA
ISSN  0094-0143 Volume 42 • Number 3 • August 2015
Elsevier
Table of Contents
Cover image
Title page
Copyright
CME Accreditation Page
Target Audience
Learning Objectives
Accreditation
Disclosure of Conflicts of Interest
Unapproved/Off-Label Use Disclosure
To Enroll
Method of Participation
CME Inquiries/Special Needs
Contributors
Consulting Editor
Editor
Authors
Forthcoming Issues
Forthcoming Issues
Recent Issues
Foreword: Testicular Cancer
Preface
Epidemiology and Diagnosis of Testis Cancer
Key points
Epidemiology
Risk factors for testis cancer
Types of germ cell tumors
Screening
Presentation and diagnosis
Staging
Metastatic spread
Prognosis
Summary
Intratubular Germ Cell Neoplasia of the Testis, Bilateral Testicular Cancer, and Aberrant Histologies
Key points
Introduction
Intratubular germ cell neoplasia
Bilateral testicular germ cell tumor
Aberrant testicular histologies
Summary
Management of Low-Stage Testicular Seminoma
Key points
Introduction
Clinical evaluation
Management of clinical stage I seminoma
Management of clinical stage IIA seminoma
Follow-up regimens
Management of Stage I Nonseminomatous Germ Cell Tumors
Key points
Epidemiology and presentation
Retroperitoneal workup and risk stratification
Management of stage I nonseminomatous germ cell tumor
Summary
The Evolution and Technique of Nerve-Sparing Retroperitoneal Lymphadenectomy
Key points
Introduction
Anatomy and physiology of ejaculation
Patient selection for nerve-sparing techniques
Technique
Outcomes
Summary
Minimally Invasive Retroperitoneal Lymphadenectomy
Key points
Introduction
Indications for retroperitoneal lymphadenectomy
Indications for postchemotherapy retroperitoneal lymphadenectomy
Technique
Approach
Outcomes
Future considerations on robotic retroperitoneal lymphadenectomy
Summary
The Role of Postchemotherapy Surgery in Germ Cell Tumors
Key points
Classifying postchemotherapy retroperitoneal lymph node dissection
Rationale for surgery after chemotherapy
Indications for postchemotherapy retroperitoneal lymph node dissection
Patient selection
Extent of dissection
Minimally invasive postchemotherapy–retroperitoneal lymph node dissection
Adjuvant procedures
Morbidity
Outcomes
Follow-up
Desperation Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Tumors
Key points
Introduction
Elevated serum tumor markers following first-line chemotherapy for germ cell tumor
Elevated serum tumor markers following second-line chemotherapy for germ cell tumor
Summary
Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors
Key points
Concept 1: cisplatin combination chemotherapy can cure even advanced germ cell patients
Concept 2: three cycles of combined cisplatin, bleomycin, and etoposide is associated with high cure rates for good-risk nonseminomatous germ cell tumors
Controversy 1: is bleomycin necessary?
Concept 3: bleomycin pulmonary toxicity is relatively rare and some factors may facilitate selection of patients at higher risk for alternate regimens
Controversy 2: is the toxicity profile of four cycles of bleomycin-free cisplatin and etoposide better than three cycles of combined cisplatin, bleomycin, and etoposide?
Concept 4: carboplatin is inferior in achieving cure for nonseminomatous germ cell tumors
Concept/controversy 5: addressing survivorship needs of patients with germ cell tumor
Summary
Late Relapse of Testicular Germ Cell Tumors
Key points
Introduction
Clinical presentation and detection of late relapse
Clinical outcomes and predictors of survival in late relapse
Prognosis and multidisciplinary treatment of late relapse
Summary
Role of Extraretroperitoneal Surgery in Patients with Metastatic Germ Cell Tumors
Key points
Introduction
Patterns of disease
Pathology
Surgical considerations
Concurrent surgery
Outcomes
Postoperative chemotherapy
Summary
Reoperative Retroperitoneal Surgery
Key points
Introduction
Testicular tumors and patterns of metastasis
Incidence, distribution, and histologic findings of retroperitoneal recurrences
Histologic findings at reoperative retroperitoneal surgery
Indications for reoperative retroperitoneal surgery
Clinical outcomes
Perioperative morbidity and complications
Summary
Long-term Morbidity of Testicular Cancer Treatment
Key points
Introduction
Second malignant neoplasms
Cardiovascular disease and Raynaud phenomenon
Pulmonary toxicity
Nephrotoxicity
Neurotoxicity
Ototoxicity
Cognitive impairment
Hypogonadism
Avascular necrosis
Recommendations for follow-up
Summary
Infertility with Testicular Cancer
Key points
Introduction
Discussion: diagnosis of male Infertility
Relationship between infertility and testicular cancer
Cancer treatment and fertility
Fertility preservation and infertility options
Summary
Index
Copyright
ELSEVIER
1600 John F. Kennedy Boulevard • Suite 1800 • Philadelphia, Pennsylvania, 19103-2899
http://www.theclinics.com
UROLOGIC CLINICS OF NORTH AMERICA Volume 42, Number 3 August 2015 ISSN 0094-0143, ISBN-13: 978-0-323-39360-7
Editor: Kerry Holland
Developmental Editor: Susan Showalter
© 2015 Elsevier Inc. All rights reserved.
This periodical and the individual contributions contained in it are protected under copyright by Elsevier, and the following terms and conditions apply to their use:
Photocopying
Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission of the Publisher and payment of a fee is required for all other photocopying, including multiple or systematic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: ([phone] (UK)/([phone] (USA).
Derivative Works
Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the Publisher is required for resale or distribution outside the institution. Permission of the Publisher is required for all other derivative works, including compilations and translations (please consult www.elsevier.com/permissions ).
Electronic Storage or Usage
Permission of the Publisher is required to store or use electronically any material contained in this periodical, including any article or part of an article (please consult www.elsevier.com/permissions ). Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the Publisher.
Notice
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made.
Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
Urologic Clinics of North America (ISSN 0094-0143) is published quarterly by Elsevier Inc., 360 Park Avenue South, New York, NY 10010-1710. Months of issue are February, May, August, and November. Business and Editorial Offices: 1600 John F. Kennedy Blvd., Suite 1800, Philadelphia, PA 19103-2899. Periodicals postage paid at New York, NY and additional mailing offices. Subscription prices are $355.00 per year (US individuals), $602.00 per year (US institutions), $415.00 per year (Canadian individuals), $752.00 per year (Canadian institutions), $515.00 per year (foreign individuals), and $752.00 per year (foreign institutions). Foreign air speed delivery is included in all Clinics subscription prices. All prices are subject to change without notice. POSTMASTER: Send address changes to Urologic Clinics of North America , Elsevier Health Sciences Division, Subscription Customer Service, 3251 Riverport Lane, Maryland Heights, MO 63043. Customer Service: 1-800-654-2452 (US). From outside the United States, call 1-314-447-8871. Fax: [phone]. E-mail: [e-mail] (for print support) and [e-mail] (for online support) .
Reprints . For copies of 100 or more, of articles in this publication, please contact the Commercial Reprints Department, Elsevier Inc., 360 Park Avenue South, New York, New York 10010-1710. Tel.: [phone]; Fax: [phone]; E-mail: [e-mail] .
Urologic Clinics of North America is covered in MEDLINE/PubMed ( Index Medicus ), Excerpta Medica, Current Contents/Clinical Medicine, Science Citation Index, and ISI/BIOMED .
Printed in the United States of America.
CME Accreditation Page


Program Objective
The goal of Urologic Clinics of North America is to keep practicing urologists and urology residents up to date with current clinical practice in urology by providing timely articles reviewing the state of the art in patient care.

Target Audience
Practicing urologists, urology residents and other health care professionals practicing in the di